
AngioDynamics (ANGO) Stock Forecast & Price Target
AngioDynamics (ANGO) Analyst Ratings
Bulls say
AngioDynamics Inc is experiencing robust growth in its Auryon product line, particularly within the office-based labs (OBL) and hospital settings, which is positively impacting its average selling prices (ASP). The company is also enhancing its gross margins, currently at 52.5%, through accelerated manufacturing initiatives and a favorable shift in revenue towards higher-margin Med-Tech products. Continued customer acquisition, increased utilization among existing accounts, and successful pricing strategies are expected to drive sustained growth for the company moving forward.
Bears say
AngioDynamics's financial outlook appears negative due to anticipated tariff headwinds estimated at $4 million to $6 million, which could adversely affect overall profitability. Furthermore, the company is bracing for increased pressure on inventory in the second half of fiscal year 2026 as a result of rising raw material costs. Despite some positive performance driven by capital sales and strong demand for NanoKnife disposables, the underlying cost pressures and external tariffs present significant risks to the company's financial stability.
This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.
AngioDynamics (ANGO) Analyst Forecast & Price Prediction
Start investing in AngioDynamics (ANGO)
Order type
Buy in
Order amount
Est. shares
0 shares